Urgent.News

What's breaking now, across thousands of outlets.

Business

Cipla partners with Qilu to license, supply Keytruda biosimilar in US

Cipla's US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical's QL2107, a biosimilar to Merck's cancer drug Keytruda, in the United States

Cipla partners with Qilu to license, supply Keytruda biosimilar in US

We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.

Read the original at business-standard.com →

More in Business

Labor Ministry Excludes Profit-Linked Bonuses from Mandatory Bargaining

The government has concluded that a labor union’s demand for performance bonuses tied to a specific percentage of a company’s operating profit does not fall under matters subject to mandatory…

  • Profit-linked bonuses not subject to mandatory bargaining
  • Legitimate demands for salary or base pay fall under bargaining
  • Management decisions on plant construction exempt from bargaining

Samsung Unveils Creator Hub at IFA 2026

Samsung Electronics is expanding its AI ecosystem at IFA 2026, Europe’s largest consumer electronics and home appliance trade show, with a dedicated platform for global influencers and content…

  • Samsung unveils Creator Hub at IFA 2026 in Berlin.
  • "A Home That Knows Me" theme features AI ecosystem showcase.
  • Samsung AI Escape Room engages users with SmartThings tech.

More from Friday 4 September →